The figure achieved by Abeona in its voucher sale tallies with other recent deals. Zevra sold a voucher in February for $150m , also to an undisclosed party. In November 2024, PTC Therapeutics ...

Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher ...

PTC said at the time that it planned to monetize the voucher, and the biopharma announced this morning that it has lined up a sale for $150 million. The company didn’t disclose the name of the ...

Combined with the cash proceeds of $148.3 million, net of fees, from the sale of the PRV after the end of the quarter, cash, cash equivalents and investments would be $217.0 million. About Zevra ...

Abeona, for its part, didn't spell out how it plans to use the proceeds from the sale. The deal comes two weeks after the company picked up FDA approval for Zevaskyn to treat recessive dystrophic ...

A priority review voucher shaves the standard 10-month review for a drug down to six months. The FDA created the program in 2012 to incentivize drug development in rare or neglected diseases.

Acadia Pharmaceuticals has bagged $150 million from the sale of a priority review voucher (PRV)—although the biotech will only be able to keep two-thirds of the windfall.

The figure achieved by Abeona in its voucher sale tallies with other recent deals. Zevra sold a voucher in February for $150m , also to an undisclosed party. In November 2024, PTC Therapeutics ...

COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash ...